Enavate Sciences - About the company
Enavate Sciences is a series D company based in United States, founded in 2022. It operates as a Provider of consulting services to improve drug discovery & development and market assessment services. Enavate Sciences has raised $300M in funding from Patient Square Capital. The company has 1407 active competitors, including 27 funded and 149 that have exited. Its top competitors include companies like Clinigen, IntegriChain and CMIC HOLDINGS.
Company Details
- Website
- enavatesciences.com
- Email ID
- *****@enavatesciences.com
Key Metrics
Founded Year
2022
Location
Stage
Series D
Total Funding
$300M in 1 round
Latest Funding Round
Investors
Ranked
17th among 1407 active competitors
Employee Count
10 - 49 as on Mar 01, 2026
Sign up to download Enavate Sciences' company profile
Enavate Sciences's funding and investors
Enavate Sciences has raised a total funding of $300M over 1 round. Its latest funding round was a Series D round on May 02, 2022 for $*****. 1 investor participated in its latest round. Enavate Sciences has 1 institutional investor.
Here is the list of recent funding rounds of Enavate Sciences:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
May 02, 2022 | 7446876 | Series D | 6105806 | 7685938 | 1513693 | 9333400 |
Access funding benchmarks and valuations. Sign up today!View details of Enavate Sciences's funding rounds and investors
Enavate Sciences' founders and board of directors
Founder? Claim ProfileEnavate Sciences' employee count trend
Enavate Sciences has 10 - 49 employees as of Mar 26. Here is Enavate Sciences's employee count trend over the years:
Uncover Enavate Sciences' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Enavate Sciences's Competitors and alternates
Top competitors of Enavate Sciences include Clinigen, IntegriChain and CMIC HOLDINGS. Here is the list of Top 10 competitors of Enavate Sciences, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Clinigen 2010, Burton-on-trent (United Kingdom), Acquired | Services in clinical trials & medicine supply | - | 59/100 | |
2nd | IntegriChain 2005, Philadelphia (United States), Acquired | Pharma commercialization solutions: data, consulting, and technology for market access | $2M | 58/100 | |
3rd | CMIC HOLDINGS 1985, Tokyo (Japan), Acquired | Contract service provider for biopharma companies | - | - | 58/100 |
4th |  Fishawack 2001, Brighton (United Kingdom), Acquired | Provider of fully-integrated, cross-border services to global pharmaceutical organisations | $23.6M | - | 57/100 |
5th | Provider of instruments for biotech, pharmaceutical, and biomedical industries | $175K | 56/100 | ||
6th |  Prescient Healthcare Group 2007, London (United Kingdom), Series B | Consulting services for product strategy and decision support | $12.7M | 56/100 | |
7th | Diaceutics 2005, Belfast (United Kingdom), Public | Analytics based integrator for precision medicine | - | 55/100 | |
8th |  Science Group 1986, Cambridge (United Kingdom), Public | Provider of product development, regulatory, and advisory services alongside the design and manufacture of systems for the defence and audio sectors | - | 49/100 | |
9th |  Spectrum Pharmatech Consultants 1995, Thane (India), Unfunded | Provider of diversified consulting services for biopharma sector | - | - | 49/100 |
10th |  Sequence 2002, Morrisville (United States), Acquired | Consulting services provider | - | - | 49/100 |
17th |  Enavate Sciences 2022, United States, Series D | Provider of consulting services to improve drug discovery & development and market assessment services | $300M | 46/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Enavate Sciences's competitors? Click here to see the top ones
Enavate Sciences's Investments and acquisitions
Enavate Sciences has not made any acquisitions yet. Enavate Sciences has made 16 investments.Here is the list of latest three $investments:
Filter this list
Filter this listDate of Investment/Acquisition | Type | Company Name | Founded Year | Location |
|---|---|---|---|---|
Jan 09, 2026 | Investments | 2024 | San Carlos (United States) | |
Dec 16, 2025 | Investments | 2025 | Irvine (United States) | |
Nov 05, 2025 | Investments | 2025 | San Francisco (United States) |
Want to know more about where corporates are investing? Sign up today!See all investments by Enavate Sciences
Reports related to Enavate Sciences
Here is the latest report on Enavate Sciences's sector:
News related to Enavate Sciences
Filter this listMedia has covered Enavate Sciences for a total of 3 events in the last 1 year.
•
AirNexis Therapeutics Raises $200M in Series A FundingFinSMEs•Jan 12, 2026•Frazier Life Sciences, Enavate Sciences, Orbimed, Goldman Sachs and 7 others
•
Enavate Sciences Invests in Braveheart Bio’s $185 Million Series A FinancingGlobal Legal Chronicle•Nov 13, 2025•Braveheart, Enavate Sciences
•
Braveheart Bio Raises $185M in Series A FundingFinSMEs•Nov 05, 2025•Frazier Life Sciences, Enavate Sciences, Orbimed, Andreessen Horowitz and 1 other
•
Aviceda secures $207.5M to launch pivotal trials for its geographic atrophy drug, AVD-104.intelligence360•Jan 17, 2025•Aviceda Therapeutics, Omega Funds, TCG Crossover, Enavate Sciences and 3 others
•
Series B financing at Normunity to advance T-cell engager into clinicBioWorld•Jan 13, 2025•Normunity, Samsara BioCapital, Enavate Sciences, Regeneron Ventures and 9 others
•
Aviceda secures $207.5M to launch pivotal trials for its geographic atrophy drug, AVD-104.Business Wire•Jan 07, 2025•Aviceda Therapeutics, Omega Funds, TCG Crossover, Enavate Sciences and 9 others
•
•
OrsoBio gains funds to develop obesity portfolioPharmaceutical Technology•Sep 09, 2024•OrsoBio, Ascenta Capital, Woodline Partners, Samsara BioCapital and 2 others
•
•
Zenas BioPharma: $200 Million Raised To Develop And Commercialize Inflammation And Immunology-Directed TherapiesPulse 2.0•May 17, 2024•Zenas BioPharma, SR One, Norwest Venture Partners, Delos Capital and 10 others
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Enavate Sciences
Explore our recently published companies
- Steakhouse Financial - Switzerland based, 2023 founded, Unfunded company
- Unity First - Boston based, 2022 founded, Unfunded company
- WP Box Sloterman - Unfunded company
- Guardian Angel Specialty Cleaners - Davenport based, Unfunded company
- Nnaemeka Nnam - Nigeria based, Unfunded company
- T&O Group - Germany based, Unfunded company
